The US Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback